Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …
Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma
Simple Summary Approximately one in seven patients with classical Hodgkin lymphoma
have refractory disease or relapse after standard front line chemotherapy. Prognostic …
have refractory disease or relapse after standard front line chemotherapy. Prognostic …
Optimizing treatment for relapsed/refractory classic hodgkin lymphoma in the era of immunotherapy
MP Randall, MA Spinner - Cancers, 2023 - mdpi.com
Simple Summary Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy,
but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage …
but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage …
T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses
X Chen, J Yu, G Venkataraman, SM Smith… - Cancer Immunology …, 2024 - AACR
The classical Hodgkin lymphoma (cHL) environment is comprised of a dense and complex
immune cell infiltrate interspersed with rare malignant Hodgkin-Reed-Sternberg (HRS) cells …
immune cell infiltrate interspersed with rare malignant Hodgkin-Reed-Sternberg (HRS) cells …
Antibody–Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab–Vedotin Exert Anti-Lymphoma and Immunostimulating Effects
Relevant advances have been made in the management of relapsed/refractory (r/r) Hodgkin
Lymphomas (HL) with the use of the anti-CD30 antibody–drug conjugate (ADC) …
Lymphomas (HL) with the use of the anti-CD30 antibody–drug conjugate (ADC) …
Mapping the Spatial Dynamics of the CD4+ T Cell Spectrum in Classical Hodgkin Lymphoma
V Menéndez, JL Solórzano, M García-Cosío… - Modern Pathology, 2024 - Elsevier
Abstract As around 25% to 30% of classical Hodgkin lymphoma (cHL) patients with
advanced stages do not respond to standard therapies, the tumor microenvironment of cHL …
advanced stages do not respond to standard therapies, the tumor microenvironment of cHL …
Location, location, location: mapping the lymphoma tumor microenvironment using spatial transcriptomics
K Pickard, E Stephenson, A Mitchell, L Jardine… - Frontiers in …, 2023 - frontiersin.org
Lymphomas are a heterogenous group of lymphoid neoplasms with a wide variety of clinical
presentations. Response to treatment and prognosis differs both between and within …
presentations. Response to treatment and prognosis differs both between and within …
The Biology of Classical Hodgkin Lymphoma
S Kosydar, SM Ansell - Seminars in Hematology, 2024 - Elsevier
Classical Hodgkin lymphoma (cHL) is distinguished by several important biological
characteristics. The presence of Hodgkin Reed Sternberg (HRS) cells is a defining feature of …
characteristics. The presence of Hodgkin Reed Sternberg (HRS) cells is a defining feature of …
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects
Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the
integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory …
integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory …
Hodgkin Lymphoma: A disease shaped by the tumor micro-and macroenvironment
R Masel, ME Roche, U Martinez-Outschoorn - Best Practice & Research …, 2023 - Elsevier
The tumor microenvironment (TMicroE) and tumor macroenvironment (TMacroE) are
defining features of classical Hodgkin lymphoma (cHL). They are of critical importance to …
defining features of classical Hodgkin lymphoma (cHL). They are of critical importance to …